Wellington Management Company

Bluejay Therapeutics Secures $182 Million in Series C Financing to Propel Clinical Pipeline

Retrieved on: 
星期四, 五月 9, 2024
T. Rowe Price, HBM, HDV, New Board, Therapy, EMA, General partnership, Wellington Management Company, Series, SAN, Global health

SAN MATEO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a leader in the development of novel therapeutics, today announced the successful closure of a $182 million Series C financing round.

Key Points: 
  • SAN MATEO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a leader in the development of novel therapeutics, today announced the successful closure of a $182 million Series C financing round.
  • This capital infusion will accelerate the clinical development of BJT-778, as the treatment for chronic hepatitis D (HDV).
  • The funds will also support the progression of additional promising candidates in Bluejay's robust pipeline for the treatment for chronic hepatitis B.
  • Following the completion of the Series C financing, Bluejay is excited to welcome New Board Member, Daniel Estes, a General Partner at Frazier, to its Board of Directors.

Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs

Retrieved on: 
星期二, 五月 7, 2024
Inflammation, NEA, Science, CD19, Patient, Pivotal, Coombs test, B cell, Wellington Management Company, Health, Norwest Venture Partners, I&I, Sclerosis, Multiple sclerosis, Pharmaceutical industry

WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology-directed therapies, today announced the closing of an upsized $200 million Series C preferred stock financing. The financing round was led by SR One along with NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences and Longitude Capital. Additional new investors, the Federated Hermes Kaufmann Funds, and Arrowmark Partners, along with existing investors, Fairmount, Wellington Management, Rock Springs Capital, Pivotal bioVenture Partners, Vivo Capital, Quan Venture Fund, and Superstring Capital participated in the financing. In conjunction with the financing, Jake Nunn, venture partner at SR One, and Tim Xiao, Partner at Delos Capital, joined Zenas’ Board of Directors.

Key Points: 
  • The financing round was led by SR One along with NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences and Longitude Capital.
  • In conjunction with the financing, Jake Nunn, venture partner at SR One, and Tim Xiao, Partner at Delos Capital, joined Zenas’ Board of Directors.
  • “Their commitment to Zenas is a testament to our vision to be a global leader in bringing innovative immunology-based therapies to patients around the world.
  • “At SR One, we invest in companies like Zenas whose science has the potential to rewrite the medical textbooks and meaningfully transform patient care.

Nilesh Undavia Calls Out GrafTech Board for Continuing to Distort the Record and Mislead Shareholders

Retrieved on: 
星期一, 五月 6, 2024
Ambiguity, NGC, Interview, Capital, Annual general meeting, Disclosure, Exercise, BLUE, CARD, GrafTech, Wellington Management Company, AUM, BOCA, UNIVERSAL, Iron, ALL, LNW, EAF, Security (finance)

BOCA RATON, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- Nilesh Undavia, one of the largest shareholders of GrafTech International Ltd. (NYSE: EAF) (“GrafTech” or the “Company”), today issued the following open letter to shareholders of the Company in connection with the election of directors for the Company’s board of directors (the “Board”) at the Company’s 2024 Annual Meeting of Shareholders (“Annual Meeting”) to be held on May 9, 2024:

Key Points: 
  • Instead, the Company has tried to distract shareholders by engaging in personal attacks and misrepresenting the truth.
  • No error would have occurred had the Company returned my calls or answered my emails requesting clarification.
  • For months, the Company has ignored and dismissed my constructive engagement, which included CEO selection criteria and long-term strategy.
  • I urge you to vote the BLUE universal proxy card TODAY to elect me, Nilesh Undavia, to the Board.

FirstSun Capital Bancorp and HomeStreet, Inc. Amend Merger Agreement

Retrieved on: 
星期二, 四月 30, 2024
Banking, Asset Management, Professional Services, Finance, Sale, Real estate, Oliver Cromwell, OTCQX, Comptroller, Commercial, Federal Reserve Bank, Amendment, Commercial property, Michael J. Hsu, Acquisition, Wellington Management Company, HomeStreet Bank, Federal Reserve, Common sunflower, OCC, Latham & Watkins

FirstSun and HomeStreet each believe that a Texas state bank charter is the appropriate charter for the combined company’s banking operations since Sunflower Bank is now headquartered in Dallas, Texas.

Key Points: 
  • FirstSun and HomeStreet each believe that a Texas state bank charter is the appropriate charter for the combined company’s banking operations since Sunflower Bank is now headquartered in Dallas, Texas.
  • Under the amended merger agreement, the necessary bank regulatory approvals required to consummate the merger are the approval of the Federal Reserve Board and the Texas Department of Banking.
  • In conjunction with the amendment to the merger agreement, the parties’ previous application with the Office of the Comptroller of the Currency (“OCC”) in connection with the bank merger has been withdrawn.
  • The remaining equity capital of up to $155 million will be issued concurrently with, and subject to, closing of the merger.

UMB Financial Corporation Announces Pricing of an Underwritten Offering of 2,800,000 Shares of Common Stock

Retrieved on: 
星期一, 四月 29, 2024
Banking, Professional Services, Finance, Bank of America, UMBF, Sale, Prospectus, RBC Capital Markets, UMB Financial Corporation, Vesey Street, Security (finance), Nicollet Mall, Form, Exercise, Varick Street, Morgan Stanley, 2nd Floor, Wellington Management Company, BofA Securities, S-3, UMB, Attention, Telephone

The underwriters have been granted the option to purchase up to an additional 420,000 shares of UMB’s common stock.

Key Points: 
  • The underwriters have been granted the option to purchase up to an additional 420,000 shares of UMB’s common stock.
  • Such borrowed shares of UMB’s common stock will be delivered by BofA Securities (in such capacity, the “forward seller”) for sale to the underwriters in the offering.
  • UMB will not receive any proceeds from the sale of the shares of its common stock sold by the forward seller to the underwriters.
  • The offering of these securities may be made only by means of a prospectus supplement and accompanying base prospectus relating to this offering.

FirstSun Capital Bancorp Reports First Quarter 2024 Results

Retrieved on: 
星期二, 四月 30, 2024
Banking, Professional Services, Finance, Sale, Table, MSR, LLP, FHLB, FTE, HTM, Environment, Wellington Management Company, Ratio, GAAP, C&I, Bank

FirstSun Capital Bancorp (“FirstSun”) (OTCQX: FSUN) reported net income of $12.3 million for the first quarter of 2024 compared to net income of $26.3 million for the first quarter of 2023.

Key Points: 
  • FirstSun Capital Bancorp (“FirstSun”) (OTCQX: FSUN) reported net income of $12.3 million for the first quarter of 2024 compared to net income of $26.3 million for the first quarter of 2023.
  • The return on average total assets was 0.64% in the first quarter of 2024, compared to 1.26% in the prior quarter, and the return on average stockholders’ equity was 5.15% in the first quarter of 2024, compared to 11.19% in the prior quarter.
  • Average loans, including loans held-for-sale, increased by $33.5 million in the first quarter of 2024, compared to the prior quarter.
  • Loan yield decreased by three basis points to 6.48% in the first quarter of 2024, compared to the prior quarter.

Wellington Management Announces Close of Inaugural Climate Innovation Fund

Retrieved on: 
星期三, 四月 17, 2024
Finance, Environment, Professional Services, Climate Change, Asset Management, Climate change, Agriculture, AI, Woodwell Climate Research Center, City, Software, Insurance, Research, Transport, Food, Wellington Management Company, Fund, Pension, Renewable energy

Wellington Management (“Wellington” or the “Firm”), one of the world’s largest independent investment management firms, today announced the final close of the Wellington Climate Innovation Fund (“CIF” or the “Fund”), with US$385 million in commitments.

Key Points: 
  • Wellington Management (“Wellington” or the “Firm”), one of the world’s largest independent investment management firms, today announced the final close of the Wellington Climate Innovation Fund (“CIF” or the “Fund”), with US$385 million in commitments.
  • CIF is Wellington’s first fund to invest solely in private companies developing solutions to help mitigate and adapt to climate change.
  • “Climate change is an existential threat to society and touches every sector of the global economy, making it one of the largest and most necessary investment opportunities we will see in our lifetimes,” said Greg Wasserman, Head of Private Climate Investing at Wellington Management.
  • The team has extensive experience investing in climate solutions and leverages Wellington’s broader investment, research and sustainability capabilities in public and private markets, along with the Firm’s research collaboration with Woodwell Climate Research Center, the leading independent climate change research institute.

Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials

Retrieved on: 
星期二, 四月 16, 2024
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Janus, Third Rock Ventures, Cancer, SCCHN, Cell, Neck, Pembrolizumab, Merck & Co., Infection, Immunotherapy, PD-1, AstraZeneca, Patient, Wellington Management Company, Renal cell carcinoma, RCC, Melanoma, Head, Toxicity, Bristol Myers Squibb, Merck, NSCLC, Autoimmunity, NK, Lung cancer, Vaccine

Asher Biotherapeutics , a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the closing of a Series C financing, which raised $55 million.

Key Points: 
  • Asher Biotherapeutics , a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the closing of a Series C financing, which raised $55 million.
  • “We are delighted to have the continued support of RA Capital, and excited to add two top biopharmaceutical companies and experts in oncology to our investor syndicate,” said Craig Gibbs, Ph.D., Chief Executive Officer of Asher Bio.
  • We are pleased to have investors with deep and hands-on expertise in the cytokine space recognizing our early clinical data and our differentiated approach.
  • Initial pharmacokinetic and pharmacodynamic data from the ongoing Phase 1a/1b clinical trial support AB248’s proof of mechanism and activity with a highly differentiated clinical profile.

UNCF 80th Anniversary Gala in Boston Raises More than $750K to Support HBCUs and Students

Retrieved on: 
星期二, 三月 12, 2024
Northeast Division, BGI, Education, University, Baupost Group, Walking, River, JPMorgan Chase, Black Economic Alliance, Wellington Management Company, Eastern Bank, UNCF, TJX Companies, Cambridge Associates, Student, Kraft Group, Vertex Pharmaceuticals, Delta Air Lines, Management

BOSTON, M.A., March 12, 2024 (GLOBE NEWSWIRE) -- March 7 brought resounding success for students of color across New England and the United States.

Key Points: 
  • BOSTON, M.A., March 12, 2024 (GLOBE NEWSWIRE) -- March 7 brought resounding success for students of color across New England and the United States.
  • Thanks to the New England UNCF (United Negro College Fund) 80th Anniversary “A Mind Is…” Gala, UNCF raised more than $750,000 to further its mission of supporting historically Black colleges and universities (HBCUs) and helping as many deserving students to get to and through college as it can.
  • The 80th anniversary event not only commemorated UNCF's rich legacy, but also emphasized its unwavering commitment to building better futures for all.
  • UNCF will continue its year-long 80th anniversary celebration in New England with a series of events that will continue to honor its legacy and transform the future for generations of minority students.

Obsidian Therapeutics Announces Oversubscribed $160.5 Million Series C Financing to Drive OBX-115 Clinical Development

Retrieved on: 
星期三, 四月 3, 2024
Biotechnology, Health, Genetics, Clinical Trials, Oncology, Janus, Growth, Novo Holdings A/S, NSCLC, TIL, Patient, Wellington Management Company, Paradigm, Foresite Capital, Bristol Myers Squibb, Lung cancer, Doctor of Philosophy, Therapy, Melanoma, Investment, Atlas Venture, Pharmaceutical industry

Obsidian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a significantly oversubscribed $160.5 million Series C financing with a top-tier syndicate of life science investors led by new investor, Wellington Management.

Key Points: 
  • Obsidian Therapeutics, Inc. , a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced it has closed a significantly oversubscribed $160.5 million Series C financing with a top-tier syndicate of life science investors led by new investor, Wellington Management.
  • Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC).
  • The Company is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.
  • “This financing provides funding through key clinical readouts in melanoma and is the catalyst to continue expanding OBX-115 into NSCLC, where there is significant potential and high unmet need.”